AI Summary
We reviewed 31 live results for hulio (adalimumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Prescription Medication.
AI Summary
We reviewed 31 live results for hulio (adalimumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Prescription Medication.
Comparison Table
Source: Biocon Biologics Ltd
Description
Hulio (adalimumab-fkjp) is a prescription biologic medication and FDA-approved biosimilar to Humira. It is a tumor necrosis factor (TNF) blocker used to treat various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. The medication is available as a citrate-free subcutaneous injection in both a 40 mg/0.8 mL pre-filled autoinjector pen and a pre-filled syringe format. As an interchangeable biosimilar, it offers a clinical alternative for patients managing autoimmune and chronic inflammatory disorders.
Best for
rheumatoid arthritis patients, inflammatory bowel disease management, cost-conscious biologic users, psoriasis treatment and subcutaneous injection therapy
Rating
Source: Viatris / Fujifilm Kyowa Kirin Biologics
Description
Hulio is an adalimumab biosimilar listed in Singapore's National Drug Formulary. It is available in 40mg/0.8ml pre-filled pens and syringes for treating inflammatory conditions such as rheumatoid arthritis and psoriasis.
Best for
immune-mediated disorders, Singapore NDF access and subcutaneous administration
Rating
Source: Biocon Biologics (Thailand) Co. Ltd
Description
Hulio is a biosimilar medication of Adalimumab used to treat various inflammatory and autoimmune conditions including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease, Ulcerative Colitis, and Plaque Psoriasis. Classified as a Special Controlled Drug in Thailand, it is typically provided as a solution for subcutaneous injection in pre-filled syringes or auto-injector pens.
Best for
rheumatoid arthritis patients, crohn's disease treatment, specialized autoimmune care and prescribed biologic therapy
Rating
| Compare | Hulio (adalimumab-fkjp) | Hulio | Hulio (Adalimumab) |
|---|---|---|---|
| Source | Biocon Biologics Ltd | Viatris / Fujifilm Kyowa Kirin Biologics | Biocon Biologics (Thailand) Co. Ltd |
| Description | Hulio (adalimumab-fkjp) is a prescription biologic medication and FDA-approved biosimilar to Humira. It is a tumor necrosis factor (TNF) blocker used to treat various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. The medication is available as a citrate-free subcutaneous injection in both a 40 mg/0.8 mL pre-filled autoinjector pen and a pre-filled syringe format. As an interchangeable biosimilar, it offers a clinical alternative for patients managing autoimmune and chronic inflammatory disorders. | Hulio is an adalimumab biosimilar listed in Singapore's National Drug Formulary. It is available in 40mg/0.8ml pre-filled pens and syringes for treating inflammatory conditions such as rheumatoid arthritis and psoriasis. | Hulio is a biosimilar medication of Adalimumab used to treat various inflammatory and autoimmune conditions including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease, Ulcerative Colitis, and Plaque Psoriasis. Classified as a Special Controlled Drug in Thailand, it is typically provided as a solution for subcutaneous injection in pre-filled syringes or auto-injector pens. |
| Best for | rheumatoid arthritis patients, inflammatory bowel disease management, cost-conscious biologic users, psoriasis treatment and subcutaneous injection therapy | immune-mediated disorders, Singapore NDF access and subcutaneous administration | rheumatoid arthritis patients, crohn's disease treatment, specialized autoimmune care and prescribed biologic therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Hulio (adalimumab-fkjp) from Biocon Biologics Ltd."
I picked this because Hulio is an excellent option for patients seeking a cost-effective, FDA-designated interchangeable biosimilar to Humira that utilizes a citrate-free formulation for injection comfort.
Share this search
Related Finds